Metis Global Partners LLC Acquires 417 Shares of Catalent, Inc. (NYSE:CTLT)

Metis Global Partners LLC grew its holdings in Catalent, Inc. (NYSE:CTLT) by 5.3% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 8,294 shares of the company’s stock after purchasing an additional 417 shares during the period. Metis Global Partners LLC’s holdings in Catalent were worth $502,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the business. Sumitomo Mitsui Trust Group Inc. increased its position in Catalent by 3.7% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 405,318 shares of the company’s stock worth $24,550,000 after purchasing an additional 14,373 shares in the last quarter. OVERSEA CHINESE BANKING Corp Ltd grew its stake in shares of Catalent by 18.8% during the third quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 6,242 shares of the company’s stock worth $378,000 after buying an additional 988 shares during the last quarter. Wolverine Asset Management LLC increased its holdings in shares of Catalent by 9.1% during the third quarter. Wolverine Asset Management LLC now owns 46,685 shares of the company’s stock worth $2,828,000 after buying an additional 3,908 shares in the last quarter. Crossmark Global Holdings Inc. lifted its stake in shares of Catalent by 2.6% in the 3rd quarter. Crossmark Global Holdings Inc. now owns 9,133 shares of the company’s stock valued at $553,000 after acquiring an additional 229 shares during the last quarter. Finally, Olympiad Research LP boosted its holdings in shares of Catalent by 93.2% during the 3rd quarter. Olympiad Research LP now owns 33,009 shares of the company’s stock valued at $1,999,000 after acquiring an additional 15,924 shares in the last quarter.

Insider Activity

In other news, Director Michelle R. Ryan sold 2,800 shares of Catalent stock in a transaction on Monday, November 11th. The shares were sold at an average price of $59.70, for a total value of $167,160.00. Following the completion of the sale, the director now owns 10,835 shares in the company, valued at $646,849.50. The trade was a 20.54 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider David Mcerlane sold 1,994 shares of the stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $59.97, for a total transaction of $119,580.18. Following the transaction, the insider now directly owns 36,304 shares in the company, valued at approximately $2,177,150.88. This represents a 5.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 5,114 shares of company stock valued at $305,931 in the last ninety days. 0.31% of the stock is owned by company insiders.

Catalent Stock Down 0.5 %

Catalent stock opened at $58.78 on Tuesday. The firm has a market cap of $10.67 billion, a price-to-earnings ratio of -26.01, a PEG ratio of 2.35 and a beta of 1.16. Catalent, Inc. has a 52-week low of $36.74 and a 52-week high of $61.20. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.96 and a current ratio of 2.51. The firm has a 50 day moving average price of $59.84 and a two-hundred day moving average price of $58.21.

Catalent (NYSE:CTLT) last announced its earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). The firm had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.06 billion. Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. Catalent’s quarterly revenue was up 4.2% on a year-over-year basis. During the same period in the prior year, the business earned ($0.10) EPS. Equities analysts predict that Catalent, Inc. will post 0.84 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have issued reports on CTLT shares. Baird R W cut Catalent from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. William Blair reaffirmed a “market perform” rating on shares of Catalent in a research note on Tuesday, September 3rd. StockNews.com upgraded shares of Catalent from a “sell” rating to a “hold” rating in a research report on Thursday, November 14th. Finally, Robert W. Baird restated a “neutral” rating and issued a $63.50 price target on shares of Catalent in a research report on Tuesday, September 24th. Eight equities research analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, Catalent presently has an average rating of “Hold” and a consensus target price of $63.40.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.